Vanda Pharmaceuticals Inc VNDA

NAS: VNDA | ISIN: US9216591084 15/09/2025

4,380 USD (-2,88%)

(-2,88%) 15/09/2025

Grafiek Vanda Pharmaceuticals Inc

Grafiek Vanda Pharmaceuticals Inc

1 dag1d -2,88%
1 week1w -2,88%
1 maand1m -3,95%
3 maanden3m -4,37%
6 maanden6m -13,78%
1 jaar1j -13,78%
5 jaar5j -54,85%

Vanda Pharmaceuticals Inc in het nieuws

Toon enkel gratis nieuws

28 augustus 2025 · Vanda Pharmaceuticals Announces Participation at September 2025 Investor Conferences · Persbericht

28 augustus 2025 · Vanda Pharmaceuticals Announces FDA Granted Orphan Drug Designation for VGT-1849B, a Novel and Selective Candidate for the Treatment of Polycythemia Vera · Persbericht

18 augustus 2025 · In a Major Win for Vanda, a Federal Appeals Court Overturns FDA's Order Denying Approval of Hetlioz for the Treatment of Jet Lag Disorder · Persbericht

31 juli 2025 · Vanda Pharmaceuticals Reports Second Quarter 2025 Financial Results · Persbericht

23 juli 2025 · Vanda Pharmaceuticals to Announce Second Quarter 2025 Financial Results on July 31, 2025 · Persbericht

10 juni 2025 · Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S · Persbericht

27 mei 2025 · Vanda Pharmaceuticals Announces Presentation at 2025 ASCP Annual Meeting · Persbericht

16 mei 2025 · Vanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit 2025 · Persbericht

7 mei 2025 · Vanda Pharmaceuticals Reports First Quarter 2025 Financial Results · Persbericht

5 mei 2025 · Vanda Announces Bysanti™ NDA Filing; FDA Decision Expected in Early 2026 · Persbericht

Profiel Vanda Pharmaceuticals Inc

Fabricage van farmaceutische preparaten

Gezondheidstechnologie

Website: www.vandapharma.com

Hoofdzetel: Washington, Washington Dc Verenigde Staten

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe